Lymphoma and Targeted Therapies

Sonali M. Smith, Julie Marie Vose

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

With further understanding of the origin of lymphoma cellular components for the various subtypes, specific pathways and targets are being identified. Many of the recent clinical trials of lymphoma therapies include targeting of specific surface antigens or cellular pathways. Over the past couple of decades, first monoclonal antibodies were developed and more recently agents that focus on pathways in B or T lymphocytes, or the microenvironment that supports the lymphoma growth. This review will focus on a selected subset of targets based on promising clinical agents for the treatment of lymphoma.

Original languageEnglish (US)
Title of host publicationTargeted Therapy in Translational Cancer Research
PublisherWiley-Blackwell
Pages169-176
Number of pages8
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
DOIs
StatePublished - Oct 30 2015

Fingerprint

Lymphoma
Therapeutics
Surface Antigens
B-Lymphocytes
Monoclonal Antibodies
Clinical Trials
T-Lymphocytes
Growth

Keywords

  • B-cell receptor pathway
  • Microenvironment
  • Monoclonal antibody
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Smith, S. M., & Vose, J. M. (2015). Lymphoma and Targeted Therapies. In Targeted Therapy in Translational Cancer Research (pp. 169-176). Wiley-Blackwell. https://doi.org/10.1002/9781118468678.ch17

Lymphoma and Targeted Therapies. / Smith, Sonali M.; Vose, Julie Marie.

Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, 2015. p. 169-176.

Research output: Chapter in Book/Report/Conference proceedingChapter

Smith, SM & Vose, JM 2015, Lymphoma and Targeted Therapies. in Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, pp. 169-176. https://doi.org/10.1002/9781118468678.ch17
Smith SM, Vose JM. Lymphoma and Targeted Therapies. In Targeted Therapy in Translational Cancer Research. Wiley-Blackwell. 2015. p. 169-176 https://doi.org/10.1002/9781118468678.ch17
Smith, Sonali M. ; Vose, Julie Marie. / Lymphoma and Targeted Therapies. Targeted Therapy in Translational Cancer Research. Wiley-Blackwell, 2015. pp. 169-176
@inbook{ba7c049ab9dc4832ba573abca040941b,
title = "Lymphoma and Targeted Therapies",
abstract = "With further understanding of the origin of lymphoma cellular components for the various subtypes, specific pathways and targets are being identified. Many of the recent clinical trials of lymphoma therapies include targeting of specific surface antigens or cellular pathways. Over the past couple of decades, first monoclonal antibodies were developed and more recently agents that focus on pathways in B or T lymphocytes, or the microenvironment that supports the lymphoma growth. This review will focus on a selected subset of targets based on promising clinical agents for the treatment of lymphoma.",
keywords = "B-cell receptor pathway, Microenvironment, Monoclonal antibody, Non-Hodgkin's lymphoma",
author = "Smith, {Sonali M.} and Vose, {Julie Marie}",
year = "2015",
month = "10",
day = "30",
doi = "10.1002/9781118468678.ch17",
language = "English (US)",
isbn = "9781118468579",
pages = "169--176",
booktitle = "Targeted Therapy in Translational Cancer Research",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Lymphoma and Targeted Therapies

AU - Smith, Sonali M.

AU - Vose, Julie Marie

PY - 2015/10/30

Y1 - 2015/10/30

N2 - With further understanding of the origin of lymphoma cellular components for the various subtypes, specific pathways and targets are being identified. Many of the recent clinical trials of lymphoma therapies include targeting of specific surface antigens or cellular pathways. Over the past couple of decades, first monoclonal antibodies were developed and more recently agents that focus on pathways in B or T lymphocytes, or the microenvironment that supports the lymphoma growth. This review will focus on a selected subset of targets based on promising clinical agents for the treatment of lymphoma.

AB - With further understanding of the origin of lymphoma cellular components for the various subtypes, specific pathways and targets are being identified. Many of the recent clinical trials of lymphoma therapies include targeting of specific surface antigens or cellular pathways. Over the past couple of decades, first monoclonal antibodies were developed and more recently agents that focus on pathways in B or T lymphocytes, or the microenvironment that supports the lymphoma growth. This review will focus on a selected subset of targets based on promising clinical agents for the treatment of lymphoma.

KW - B-cell receptor pathway

KW - Microenvironment

KW - Monoclonal antibody

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85015898327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015898327&partnerID=8YFLogxK

U2 - 10.1002/9781118468678.ch17

DO - 10.1002/9781118468678.ch17

M3 - Chapter

AN - SCOPUS:85015898327

SN - 9781118468579

SP - 169

EP - 176

BT - Targeted Therapy in Translational Cancer Research

PB - Wiley-Blackwell

ER -